Abstract
The uses of synthetic heme analogues that are competitive inhibitors of heme oxygenase, the rate-limiting enzyme in the production of bilirubin, represent a novel means of controlling severe hyperbilirubinemia in the newborn. The logic of this approach and the use of stannsoporfin (tin mesoporphyrin) as the compound of choice are discussed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Enzyme Inhibitors / therapeutic use*
-
Heme Oxygenase (Decyclizing) / antagonists & inhibitors*
-
Humans
-
Infant, Newborn
-
Jaundice, Neonatal / prevention & control*
-
Metalloporphyrins / therapeutic use*
Substances
-
Enzyme Inhibitors
-
Metalloporphyrins
-
tin mesoporphyrin
-
Heme Oxygenase (Decyclizing)